New approaches to the pathogenesis, clinic, and treatment of hepatic encephalopathy
- Authors: Podymova S.D.1
-
Affiliations:
- Loginov Moscow Clinical Research and Practical Center
- Issue: Vol 93, No 2 (2021)
- Pages: 236-242
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/64878
- DOI: https://doi.org/10.26442/00403660.2021.02.200613
- ID: 64878
Cite item
Full Text
Abstract
This review article presents new approaches to the assessment of key pathogenesis factors, clinical features, and treatment of hepatic encephalopathy (HE) associated with liver cirrhosis. Various clinical variants of the course of HE in patients with cirrhosis of the liver areconsidered, which are important for the choice of treatment and prevention of repeated relapses of HE. Analyzed the ammonia hypothesis of pathogenesis and associated hyperammonemia, which is the basis of most modern treatment methods. These data on the activation of the adaptive pathway for removing ammonia in the form of glutamine are used in the further study of drugs that enhance the clearance of ammonia. The possibility of reducing GABA-ergic tone due to the effect of the antagonist on the neurosteroid site in the GABA receptor complex is emphasized.
Full Text
##article.viewOnOriginalSite##About the authors
S. D. Podymova
Loginov Moscow Clinical Research and Practical Center
Author for correspondence.
Email: spodymova@yandex.ru
ORCID iD: 0000-0002-2313-9748
д.м.н., проф., вед. науч. сотр. отд. гепатологии
Russian Federation, MoscowReferences
- Ferenci P, Lockwood A, Mullen K, et al: Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-21. doi: 10.1053/jhep.2002.31250
- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-35. doi: 10.1002/hep.27210
- Подымова С.Д. Печеночная энцефалопатия, связанная с циррозом печени. Современные подходы к патогенезу, клинике, лечению. Эксперим. и клин. гастроэнтерология. 2017;11:4-12 [Podymova SD. Hepatic encephalopathy associated with cirrhosis of the liver. Modern approaches to pathogenesis, clinic, and treatment. Experimental and clinical gastroenterology. 2017;11:4-12 (In Russ.)].
- Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl. 1):3-9. doi: 10.1111/j.1746-6342.2006.03215.x
- Wolf DC. Hepatic Encephalopathy. Available at: https://emedicine.medscape.com/article/186101-print. Accessed: 06.11.2019
- Wang A-J, Peng A-P, Li B-M, et al. Natural history of covert hepatic encephalopathy: Anobservational study of 366 cirrhotic patients Observational Study. World J Gastroenterol. 2017;23(34):6321-9. doi: 10.3748/wjg.v23.i34.6321
- Benvegnoù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-9. doi: 10.1136/gut.2003.020263
- Watson H, Jepsen P, Wong F, et al. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis. 2013;28:301-5. doi: 10.1007/s11011-013-9384-4
- Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-5. doi: 10.1016/s0168-8278(99)80144-5
- Butterworth RF, Giguere JF, Michaud J, et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987;6:1-12. doi: 10.1007/BF02833598
- Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology. 2011;53:1372-6. doi: 10.1002/hep.24228
- Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis. 2007;22:309-20. doi: 10.1007/s11011-007-9072-3
- Chatauret N, Butterworth RF. Effects of liver failure on inter-organ trafficking of ammonia: implications for the treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2004.19:S219-23
- Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy-an ISHEN consensus statement. Aliment Farmacol Ther. 2011;33:739-47. doi: 10.1111/j.1365-2036.2011.04590.x
- Butterworth RF. Hepatic encephalopathy in Cirrhosis: Pathology and Pathophysiology. Drugs. 2019;79(Suppl. 1):S17-21. doi: 10.1007/s40265-018-1017-0
- Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol. 2015;21(41):11815-24. doi: 10.3748/wjg.v21.i41.11815
- Подымова С.Д. Болезни печени: руководство для врачей. Изд. 5-е, перераб. и доп. М.: Мед. информационное агенство, 2018 [Podymova SD. Liver Diseases: Manual. The 5th ed, rev. and add. Moscow: Medical Informational Agency, 2018 (In Russ.)].
- Ahboucha S, Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis. 2004;19(3-4):331-43. doi: 10.1023/b:mebr.0000043979.58915.41
- Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol. 2016;160:94-7. doi: 10.1016/j.jsbmb.2015.11.006
- Butterworth RF. The astrocytic (“peripheral-type”) benzodiazepine receptor: role in the pathogenesis of portal-systemic encephalopathy. Neurochem Int. 2000;36(4-5):411-6. doi: 10.1016/s0197-0186(99)00132-1
- Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60(4):521-8. doi: 10.1001/archneur.60.4.521
- Kok B, Foxton MR, Clough C, Shawcross DL. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy. Hepatology. 2013;58(4):1516-7. doi: 10.1002/hep.26364
- Caldwell C, Werdiger N, Jakab S, et al. Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transpl. 2010;16(7):818-26. doi: 10.1002/lt.22077
- Conn HO, Rossle M, Levy L, Glocker FX. Portosystemic myelopathy: spastic paraparesis after portosystemic shunting. Scand J Gastroenterol. 2006;41(5):619-25. doi: 10.1080/00365520500318932
- Butterworth RF. Editorial: rifaximin and minimal hepatic encephalopathy. Am J Gastroenterol. 2011;106(2):317-8. doi: 10.1038/ajg.2010.460
- Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2008;2:785-90. doi: 10.1586/17474124.2.6.785
- Дамулин И.В. Минимальная печеночная энцефалопатия: современные клинические и патогенетические аспекты. Терапевтический архив. 2018;90(2):89-92. [Damulin IV. Minimal hepatic encephalopathy: current clinical and pathogenetic aspects. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(2):89-92 (In Russ.)]. doi: 10.26442/terarkh201890289-93
- EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172-93. doi: 10.1016/j.hep.2018
- Sharma BC, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885-91. doi: 10.1053/j.gastro.2009.05.056; ID: 19779523
- Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43(Suppl. 1):11-26. doi: 10.1111/apt.13435
- Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-50. doi: 10.1097/MEG.0000000000001311
- Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25(6):1351-60. doi: 10.1002/HEP.510250609; ID: 20483124
- Ong JP, Oehler G, Kruger-Jansen C et al. Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patient with Hepatic Encephalopathy/An Open-Label, Prospective, Multicentre Observational Study. Clin Drug Investig. 2011;1(4):213-20. doi: 10.2165/11586700-000000000-00000
- Johansson M, Agusti A, Llansola M, et al. GR3027 antagonizes GABA A-receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalhopathy. Am J Physiol Gastrointest Liver Physiol. 2015;309:G400-9. doi: 10.1152/ajpgi.00073; ID: 1352144
- Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015; 9:CD001939. doi: 10.1002/14651858.CD001939.pub3
- Chavez-Tapia NC, et al. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74 http://www.nutritionj.com/content/12/1/74
- Shen C, et al. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18:34. doi: 10.1186/s12937-019-046